Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
- Referrals to patient-related programs or resources
- Donations, website, or event-related assistance
- Tobacco-related topics
- Volunteer opportunities
- Cancer Information
For medical questions, we encourage you to review our information with your doctor.
- Triggering Signals of BRCA1 Breast Cancer (K Kessenbrock)
- Testing Diverse Groups Finds New Breast Cancer Genes (L Teras)
- Black Women & Genetic Testing (J Palmer)
- Women 65+ & Genetic Tests for Breast Cancer Risk (L Teras)
- High-Risk Genes and Screening (A Patel)
- New Risk Calculation May Affect Breast Cancer Screening (L Teras)
- Black Men and Breast Cancer (H Sung)
- Platelets May Help Breast Cancer Spread (E Battinelli)
- Natural Killer Cells & TNBC (R. Chakrabarti)
- Improving Chemotherapy (O Sahin)
- Combo Treatment for TNBC (K Varley)
- Treatments Attack Cell Division (A Holland)
- ER+ Treatment in Mice (P Kenny)
- Blood DNA Monitors Metastasis Treatment (H P Ji)
- PTK6 Gene as Treatment Target (H Irie)
- Time-Lapse Cell Movies (S Spencer)
- 3D Mini Breast Tumors May Help ID New Cancer Treatments
- AI Tool Improves Breast Cancer Prognosis Accuracy
- Exercise & Sitting Time (E. Rees-Punia)
- Cancer Risk Factors in LGBTQ Populations (B. Charlton)
- CPS-3 Disparities Studies
- Cancer Disparities in the US (F. Islami)
- Housing Assistance and Mammograms (H Lee)
- Clinical Trial Treatment Cost App (L Hamel)
- Podcasts, TheoryLab
- Patients Health Insurance Tool (M. Politi)
- Breast Cancer Treatment in Ethiopia (A. Jemal)
- Better Survival Requires Better Insurance (J Zhao)
- Medicaid Eligibility Limits (J Zhao)
- New Treatment for Neuroblastoma (A Heczey)
- Oncogenic Fusions AML (S Meshinchi)
- Genetic Risks (L Teras)
- New Medulloblastoma Drugs (J Rodriguez-Blanco)
- Potential New Hope for MLL (J Grembecka)
- Increase in Brain Tumor Diagnosis (K Miller)
- Longer Life Expectancy for Survivors (J Yeh)
- Potential Target for New Osteosarcoma Drugs (C Benavente)
- At-Home Chemo for Children with HR ALL (L Ranney)
- Childhood Cancer Research Landscape Report
- Tumor-Infiltrating Neutrophils (R. Sumagin)
- New Epigenetic Target (K Rai)
- Extra Chromosomes (Aneuploidy) Effect on Cancer (J. Sheltzer)
- Discovery of a New Biomarker Is the First Step to New Treatment (C. Maher)
- Designer Virus Targets and Kills CRC Cells in Mice (S. Warner)
- Tiny Sensor in Mice May Find Cancer That's Trying to Spread (L. Hao)
- Targeting a Protein “Turned on” by Mistake (N. Gao)
- Spatial Map Intestines (J Hickey)
- CRC Treatment Podcasts
- Keto Molecule & Colorectal Cancer (M Levy)
- Availability of Healthy Food (L Tussing-Humphreys)
- 45 Min/Day of Physical Activity (A Minihan)
- Fewer than 10K Steps/Day (A Patel)
- Yogurt & Cheese & ER- Breast Cancer (M McCullough)
- Stage 2 Clinical Trials for New Endometrial Cancer Drug (V Bae-Jump)
- Hard-to-Starve Pancreatic Cancer Cells (N Kalaany)
- Coffee Risks for Colorectal Cancer (C Um)
- Food Parasite & Brain Cancer Risk (J Hodge)
- Exercise & Quality of Life in Older Survivors (E Rees-Punia)
- 21 Metabolites Linked with Breast Cancer (Y Wang)
- Replacing Sitting May Affect Weight (E Rees-Punia)
- CPS-3 Researchers Ask What People Eat and Check Urine Samples (Y Wang)
- Video Games Motivate Exercise? (E. Lyons)
- Food Choices and Colon Cancer Risk (P. Chandler)
- Race, Exercise & Breast Cancer (C. Dallal)
- Diet with Colorectal Cancer (M. Guinter)
- Biomarkers May Improve Prediction (Y Wang)
- Kickstart NSCLCs Clinical Trials (L. Eichner)
- Mapping Mitochondria's “Dance” (D. Shackleford)
- E-Cig Use Ages 18 to 29 (P. Bandi)
- Stopping Smoking Earlier in Life (F Islami)
- Most with Lung Cancer Smoked (A Jemal)
- Furthering Lung Cancer Screening & Equity (S Fedewa)
- Mouse Lung Organoids for Research (C Kim)
- Quality of Life for Lung Cancer Survivors (J Temel)
- Precision Therapies for NSCLC (P Jänne)
- Cancer Deaths from Smoking (F Islami)
- Lung Cancer Surgery Disparities (A Jemal)
- BRG1-Deficient Lung Cancers (C Kim)
- Yoga for Couples with Lung Cancer (K Milbury)
- Metabolic Differences as New Drug Targets (A Marcus)
- CPS-II & CPS-3 Inform About Risks of Ovarian Cancer
- Machine Learning & Glowing Nanosensors (D Heller)
- Ovarian Cancer May Start in Fallopian Tube Cells (K Lawrenson)
- New Gene Linked with Deadliest Type (C Han)
- Gene-Testing Tools May Personalize Care (A Sood)
- Chromosome-Hoarding Ovarian Cancer Cells & Treatment (J Sheltzer)
- Nanoparticles as Drug Delivery for Metastases (X Lu)
- Turning Off 2 Proteins to Slow HGSC (P Kreeger)
- Targeted Light Therapy in Mice (M Bai)
- Nanoparticles, CAR T, and CRISPR (M Stephan)
- Endometriosis & Ovarian Cancer in Mice (M Wilson)
- Ovarian Cancer Special Section
- UV Exposure, Melanoma, & Dark Skin Types (A. Adamson)
- Melanoma and Lipid Droplets (R. White)
- Zebrafish and Acral Melanoma (R. White)
- T-Cell Lymphoma and PD1 (J. Choi)
- New Drug Destroys Cancer-Causing Protein (C. Crews)
- Virus & Merkel Cell Skin Cancer (R. Wang)
- Non-Genetic Drug Resistance (S. Spencer)
- Hijacking the Body's Sugar (R. Wang)
- Telling about High Risk (P. Kanetsky)
- Brain Metastasis and Alzheimer’s (E. Hernando)
- Exhausted Melanoma "Killer" Cells (W. Cui)
Can Ozempic & Mounjaro Reduce the Risk of Colorectal Cancer?
Early study finds GLP-1 medicines reduce the risk of colorectal cancer more than other diabetes medicines, especially for people with overweight/obesity.
The Challenge
People with overweight or obesity may have a higher risk of developing colorectal cancer as well as 12 other types of cancer compared to people without those conditions.
People with type 2 diabetes may also have an increased risk of developing colorectal cancer. And, the risk of developing type 2 diabetes may be higher for people who have obesity or overweight.
People may assume that losing weight could reduce the risk of developing both conditions. However, research on whether losing weight might lower the risk of developing cancer—including colorectal cancer—is limited. (Evidence is growing that intentional weight loss may lower the risk of developing breast cancer after menopause and endometrial cancer.)
There is, however, evidence that losing weight may lower the risk of developing type 2 diabetes. For people already diagnosed with type 2 diabetes, there’s evidence that losing weight may help reduce complications from the condition.
According to the American Diabetes Association (ADA) Standards of Care in Diabetes, 2024: “There is strong and consistent evidence that obesity management can delay the progression from prediabetes to type 2 diabetes and is highly beneficial in treating type 2 diabetes.”
Currently, there’s a newer class of medicines, known as GLP-1s, that are getting a lot of media attention because they are used to treat type 2 diabetes, and some are also approved for weight loss.
Not surprisingly, some researchers are asking—could the GLP-1s used to treat type 2 diabetes and overweight/obesity one day be used to lower the risk of developing colorectal cancer?
Popular GLP-1 Medicines
Also known as GLP-1 receptor agonists or GLP-1Ras, the acronym GLP-1 stands for glucagon-like peptide-1. Most people are more familiar with one of the often more popular brand names. Some of these are approved for treating people with type 2 diabetes, overweight/obesity, or both.
Approved for Type 2 Diabetes (weight loss may occur as a side effect)
- Adlyxin
- Bydureon
- Byetta
- Mounjaro (a GLP-1/GIP receptor agonist)
- Ozempic
- Rybelsus
- Trulicity
- Victoza
Approved for Overweight/Obesity
- Saxenda
- Wegovy
- Zepbound
The Research
Rong Xu, PhD, recently published a research letter in JAMA Oncology that described a study partially funded by a grant from the American Cancer Society (ACS). The study was based on the hypothesis that GLP-1s would reduce the risk of developing colorectal cancer better than other diabetes medicines.
Xu co-led the study and worked with fellow researchers from Case Western Reserve School of Medicine and The MetroHealth System in Cleveland. They used a special platform to analyze the electronic health records of more than 1 million patients from 59 health care organizations across 50 states. In that group, over 7 million had type 2 diabetes.
They honed the study group to just over 1.2 million patients with type 2 diabetes and without a diagnosis of colorectal cancer. They studied the group for 15 years—from 2005 to 2019. During that period, patients were prescribed a diabetes medication for the first time.
The researchers compared the use of GLP-1s with 7 types of diabetes treatments. They also analyzed people with overweight/obesity and those without either condition.
Findings for People with Type 2 Diabetes and without Obesity/Overweight
GLP-1s were associated with a decreased risk of developing colorectal cancer compared with most types of other diabetes medicines in people with type 2 diabetes and without obesity/overweight. Specifically, the group taking a GLP-1 had a lower incidence of colorectal cancer than those in groups taking insulin, metformin, SGLT2 inhibitors, sulfonylureas, or thiazolidinediones.
- GLP-1s vs Insulin. Among the 22,572 people with diabetes and without obesity/overweight who received insulin, the researchers identified 167 cases of colorectal cancer. Among the 22,572 matched people treated with GLP-1, they identified only 94 cases of colorectal cancer. That represents a 44% decreased incidence of colorectal cancer for those who took a GLP-1 medicine compared to those who took insulin to treat type 2 diabetes without obesity/overweight.
- GLP-1s vs Metformin. In a similar comparison, the researchers found a 25% decreased incidence of colorectal cancer for people with type 2 diabetes and without obesity/overweight who took a GLP-1 medicine vs those taking metformin to treat type 2 diabetes without obesity/overweight.
GLP-1s were associated with a lower—but not statistically significant—risk for colorectal cancer compared with alpha-glucosidase and DPP-4 inhibitors thiazolidinediones in people with type 2 diabetes and without obesity/overweight.
Findings for People with Type 2 Diabetes and with Obesity/Overweight
GLP-1s were associated with a lower risk for colorectal cancer compared with all types of diabetes medicines.
- GLP-1s vs Insulin. Among the 9,398 people with type 2 diabetes and overweight/obesity who received insulin, the researchers identified 67 cases of colorectal cancer. Among the 9,398 matched people treated with GLP-1, they identified 35 cases of colorectal cancer. That represents a 50% decreased incidence of colorectal cancer for those who took a GLP-1 medicine compared to those taking insulin.
- GLP-1s vs Metformin. In a similar comparison, the researchers found a 42% decreased incidence of colorectal cancer for those taking a GLP-1 medicine compared to those who took metformin.
Their findings were consistent between men and women.
Both the group of people with overweight/obesity and without it had fewer cases of colorectal cancer in people who received a GLP-1 medicine compared with one of the other diabetes medicines. But we found more profound effects in the group of people with obesity/overweight and type 2 diabetes. This suggests that GLP-1 medicines have a potential protective effect against colorectal cancer, which may be partly due to losing weight and partly due to other mechanisms not related to weight loss.”
Rong Xu, PhD
Center for AI in Drug Discovery and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine
Former American Cancer Society Grantee
“To our knowledge, this is the first study about this class of popular weight loss and diabetes drugs to show a reduced incidence of colorectal cancer compared with other antidiabetic drugs,” Xu added.
What does ‘matched people’ mean?
To accurately compare the drugs’ effects, the researchers matched patients between cohorts based on:
- Adverse socioeconomic determinants of health (housing and economic circumstance, upbringing, education, physical environment, social environment)
- Demographics
- Family and personal history of cancer and polyps in the colon
- Family circumstance
- Lifestyle factors (exercise, diet, smoking, and alcohol drinking)
- Preexisting conditions (overweight, obesity, ulcerative colitis, or cystic fibrosis)
- Procedures received (bariatric surgery, colonoscopy, and radiation therapy)
Why It Matters
Large retrospective population research like this observational study can find correlations but cannot prove causations. That is, this study doesn’t prove that taking GLP-1s reduces the risk of developing colorectal cancer risk, but its findings warrant further investigation with clinical trials.
This exciting data also paves the way for additional studies including testing whether GLP-1s reduce the risk of other types of cancer associated with obesity.